Q2i is a Digital Health Company

dedicated to developing, refining, validating, and commercializing innovative, evidence-based solutions.

Q2i’s technology is developed with
the support of, and in conjunction with:

Q2i's academic partners include:

Q2i Research Projects

Project Title

Date started

Status

Academic Partner/s

Buprenorphine induction low-dose to depot (build2depot): development of safe rapid transfer to depot medication and go/no go testing potential of remote community-based monitoring.

2024

In recruitment phase

Prison release engagement trial, smartphone app to improve continuity of care post release for released prisoners (RPS) who want to stay drugfree

2024

In recruitment phase

PARCA (a digital tool) to improve justice and health

2023

Phase I STTR successfully completed, and now in Phase II (Dallas and Austin)

Digital health technology improving successful community reintegration of recently released justice involved individuals with substance use disorders

2020

Phase I STTR successfully completed – results published

Reward-Based technology to improve opioid use disorder treatment after an ED visit

2019

Phase I and Phase II STTR successfully completed Completed – in data analysis phase

Technology improving the success of medication assisted treatment in primary care

2019

Phase I and Phase II STTR successfully completed – Manuscript drafted ready for peer review

Contact Us

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*